CVS Health Corp (NYSE:CVS) COO Sells $4,180,800.69 in Stock
CVS Health Corp (NYSE:CVS) COO Jonathan C. Roberts sold 57,563 shares of the stock in a transaction dated Wednesday, January 8th. The shares were sold at an average price of $72.63, for a total transaction of $4,180,800.69. Following the completion of the sale, the chief operating officer now owns 102,608 shares of the company’s stock, valued at approximately $7,452,419.04. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
NYSE:CVS traded down $0.75 on Friday, reaching $72.11. 5,196,246 shares of the company’s stock were exchanged, compared to its average volume of 5,603,462. The company has a debt-to-equity ratio of 1.32, a current ratio of 0.92 and a quick ratio of 0.61. The firm has a market cap of $94.53 billion, a price-to-earnings ratio of 10.19, a P/E/G ratio of 1.54 and a beta of 0.89. CVS Health Corp has a 52 week low of $51.72 and a 52 week high of $77.03. The stock has a fifty day simple moving average of $74.42 and a 200-day simple moving average of $64.75.
CVS Health (NYSE:CVS) last issued its earnings results on Wednesday, November 6th. The pharmacy operator reported $1.84 earnings per share for the quarter, topping analysts’ consensus estimates of $1.77 by $0.07. The firm had revenue of $64.81 billion during the quarter, compared to analyst estimates of $62.99 billion. CVS Health had a net margin of 1.83% and a return on equity of 15.45%. The company’s quarterly revenue was up 36.5% on a year-over-year basis. During the same quarter last year, the business earned $1.73 earnings per share. As a group, sell-side analysts predict that CVS Health Corp will post 7.03 EPS for the current year.
A number of research firms recently issued reports on CVS. Bank of America raised their price objective on shares of CVS Health from $72.00 to $75.00 and gave the stock a “buy” rating in a report on Thursday, September 12th. Mizuho raised their price objective on shares of CVS Health from $71.00 to $82.00 and gave the stock a “buy” rating in a report on Friday, November 8th. Cowen set a $76.00 price objective on shares of CVS Health and gave the stock a “buy” rating in a report on Monday, October 21st. Raymond James restated a “strong-buy” rating and set a $90.00 price objective (up previously from $80.00) on shares of CVS Health in a report on Wednesday, December 4th. Finally, JPMorgan Chase & Co. raised their price objective on shares of CVS Health from $88.00 to $97.00 and gave the stock an “overweight” rating in a report on Thursday, December 19th. One analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $77.43.
A number of large investors have recently modified their holdings of CVS. Nuveen Asset Management LLC boosted its position in CVS Health by 16,194.7% during the second quarter. Nuveen Asset Management LLC now owns 12,112,044 shares of the pharmacy operator’s stock worth $659,986,000 after purchasing an additional 12,037,713 shares during the period. Morgan Stanley boosted its position in CVS Health by 12.8% during the second quarter. Morgan Stanley now owns 13,765,635 shares of the pharmacy operator’s stock worth $750,088,000 after purchasing an additional 1,560,142 shares during the period. Macquarie Group Ltd. boosted its position in CVS Health by 10.9% during the second quarter. Macquarie Group Ltd. now owns 13,905,440 shares of the pharmacy operator’s stock worth $757,707,000 after purchasing an additional 1,372,275 shares during the period. Prudential PLC boosted its position in CVS Health by 54.8% during the second quarter. Prudential PLC now owns 3,737,874 shares of the pharmacy operator’s stock worth $203,137,000 after purchasing an additional 1,323,366 shares during the period. Finally, Vanguard Group Inc. boosted its position in CVS Health by 1.2% during the second quarter. Vanguard Group Inc. now owns 102,367,899 shares of the pharmacy operator’s stock worth $5,578,027,000 after purchasing an additional 1,167,143 shares during the period. Hedge funds and other institutional investors own 76.65% of the company’s stock.
About CVS Health
CVS Health Corporation provides health services and plans in the United States. Its Pharmacy Services segment offers pharmacy benefit management solutions, such as plan design and administration, formulary management, retail pharmacy network management, mail order pharmacy, specialty pharmacy and infusion, Medicare Part D, clinical, disease management, and medical spend management services.
Recommended Story: Understanding Analyst Recommendations
Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.